

Tecentriq® (atezolizumab) & Tecentriq Hybreza® (atezolizumab/hyaluronidase-tqjs)
Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician Billing (HCPCS code): _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria***Page 1 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.***
For Initial Authorization:

1. Please indicate the diagnosis and information:

 Non-Squamous Non-Small Cell Lung Cancer (NSCLC)A. Will atezolizumab be used as first-line therapy for metastatic disease? Yes No B. Does member have epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, BRAF, MET exon 14 skipping, or RET mutations? Yes No C. Will atezolizumab be used in combination with bevacizumab, paclitaxel, and carboplatin?
Yes No

i. If yes to the above question, please indicate the number of cycles: _____

D. Will atezolizumab be used in combination with paclitaxel (protein bound) and carboplatin?
Yes No **Non-Small Cell Lung Cancer (NSCLC)**A. Will atezolizumab be used as first-line therapy for metastatic disease? Yes No i. If yes, will atezolizumab be used as a single-agent? Yes No ii. If yes, does member have EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, or RET mutations?
Yes No

iii. If yes, does disease have high programmed death ligand-1 (PD-L1) expression determined by the following [check applicable box(es)]?

 PD-L1 stained >50% of tumor cells (TC>50%) PD-L1 stained tumor-infiltrating immune cells (IC) covering >10% of the tumor area (IC>10%)B. Will atezolizumab be used for subsequent therapy for metastatic disease? Yes No i. If yes, will atezolizumab be used as a single-agent? Yes No C. Is diagnosis stage 2 or 3A NSCLC? Yes No i. If yes, has member has undergone resection and completed platinum-based chemotherapy?
Yes No ii. Is PD-L1 expression $\geq 1\%$ of tumor cells? Yes No **(Page 1 of 2)****CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.
All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

Tecentriq® (atezolizumab) & Tecentriq Hybreza® (atezolizumab/hyaluronidase-tqjs) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Criteria

Page 2 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.

For Initial Authorization, continued::

1. Please indicate the diagnosis and information, continued:

Small Cell Lung Cancer (SCLC)

A. Will atezolizumab be used as first-line therapy? Yes No

B. Does member have extensive-stage disease? Yes No

C. Will atezolizumab be used in combination with carboplatin and etoposide? Yes No

Hepatocellular Carcinoma (HCC)

A. Is diagnosis advanced, unresectable, or metastatic HCC? Yes No

B. Will atezolizumab be used in combination with bevacizumab? Yes No

C. Has member received prior systemic therapy? Yes No

Melanoma

A. Is diagnosis unresectable or metastatic melanoma? Yes No

B. Is disease BRAF V600 mutation-positive? Yes No

C. Will atezolizumab be used in combination with cobimetinib and vemurafenib? Yes No

Alveolar Soft Part Sarcoma (ASPS)

A. Is ASPS unresectable or metastatic? Yes No

If diagnosis is not listed, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on atezolizumab? Yes No

i. If "No" to the above question, was atezolizumab used in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC? Yes No

ii. If used in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC, how many cycles has the member received? _____

iii. Will atezolizumab be used in combination with bevacizumab for continued treatment? Yes No

3. Has the member experienced adverse drug reactions related to atezolizumab therapy? Yes No

i. If yes, please specify adverse reactions: _____

Additional information: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Page 2 of 2

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.